£7.8m market cap

2.9p last close

e-Therapeutics is a UK-based drug discovery company that has developed a proprietary network-driven drug discovery platform that has generated pre-clinical licensing opportunities.

Investment summary

e-Therapeutics (ETX) offers investors exposure to a proprietary, cutting-edge in silico network-driven drug discovery (NDD) platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated two new chemical entities in immunoncology that are the subject of business development efforts and have achieved commercial validation through the deal with Novo Nordisk. ETX’s priority is securing further partnerships to provide external validation and it has recently signed deals to enhance the NDD platform with AI and a discovery deal with C4XD. ETX’s strength is in complex disease networks such as cancer.

Y/E Jan
Revenue (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2018A 0.0 (6.7) (6.7) (2.0) N/A N/A
2019A 0.0 (5.1) (5.1) (1.51) N/A N/A
2020E 0.5 (3.5) (3.5) (0.9) N/A N/A
2021E 0.0 (3.0) (3.0) (0.8) N/A N/A
Industry outlook

Network-driven approaches could revolutionise drug discovery and shorten the path to market by minimising technical risks and drug development costs. ETX is differentiated from its competitors through its expertise in curating, processing and analysing data in the context of the mechanistic modelling of disease.

Last updated on 25/07/2019
Share price graph
Balance sheet
Forecast net cash (£m) 3.8
Forecast gearing ratio (%) N/A
Price performance
Actual 93.3 (6.5) (59.2)
Relative* 91.2 (6.9) (58.0)
52-week high/low 8.2p/1.5p
*% relative to local index
Key management
Iain Ross Chairman
Raymond Barlow CEO
Steve Medlicott CFO

Content on e-Therapeutics